Allergan Says New Data Supports Continued Development of Cenicriviroc For Treating Liver Fibrosis

Allergan (AGN) was out Friday with top-line results from new data for the Centaur phase 2b study which it says supports the anti-fibrotic efficacy and safety of Cenicriviroc for the treatment of liver fibrosis in adults with non-alcoholic steatohepatitis.

One year data from the Centaur trial was released in 2016. The new data released Friday includes patients who remained on treatment for two years, as well as patients who received placebo in year one and then crossed-over to Cenicriviroc for the second year.

Allergan is currently enrolling patients in a 2,000 patient phase 3 clinical trial of Cenicriviroc called the Aurora trial. The company plans to conduct additional subanalyses of the Centaur study and will discuss the data with regulatory authorities to determine whether study modifications may be required.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.